The Combined Impact of CLIR Post-Analytical Tools and Second Tier Testing on the Performance of Newborn Screening for Disorders of Propionate, Methionine, and Cobalamin Metabolism

被引:20
作者
Gavrilov, Dimitar K. [1 ]
Piazza, Amy L. [1 ]
Pino, Gisele [1 ]
Turgeon, Coleman [1 ]
Matern, Dietrich [1 ]
Oglesbee, Devin [1 ]
Raymond, Kimiyo [1 ]
Tortorelli, Silvia [1 ]
Rinaldo, Piero [1 ]
机构
[1] Mayo Clin, Biochem Genet Lab, Dept Lab Med & Pathol, Rochester, MN 55905 USA
关键词
Collaborative Laboratory Integrated Reports (CLIR); false positive rate; newborn screening (NBS); second tier test (2TT); DRIED BLOOD SPOTS; TANDEM MASS-SPECTROMETRY; FALSE-POSITIVE RATE; LIQUID-CHROMATOGRAPHY; TOTAL HOMOCYSTEINE; 2ND-TIER TEST; REMETHYLATION DISORDERS; 2-METHYLCITRIC ACID; METHYLMALONIC ACID; AMINO-ACIDS;
D O I
10.3390/ijns6020033
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The expansion of the recommend uniform screening panel to include more than 50 primary and secondary target conditions has resulted in a substantial increase of false positive results. As an alternative to subjective manipulation of cutoff values and overutilization of molecular testing, here we describe the performance outcome of an algorithm for disorders of methionine, cobalamin, and propionate metabolism that includes: (1) first tier screening inclusive of the broadest available spectrum of markers measured by tandem mass spectrometry; (2) integration of all results into a score of likelihood of disease for each target condition calculated by post-analytical interpretive tools created byCollaborative Laboratory Integrated Reports (CLIR), a multivariate pattern recognition software; and (3) further evaluation of abnormal scores by a second tier test measuring homocysteine, methylmalonic acid, and methylcitric acid. This approach can consistently reduce false positive rates to a <0.01% level, which is the threshold of precision newborn screening. We postulate that broader adoption of this algorithm could lead to substantial savings in health care expenditures. More importantly, it could prevent the stress and anxiety experienced by many families when faced with an abnormal newborn screening result that is later resolved as a false positive outcome.
引用
收藏
页数:13
相关论文
共 39 条
[1]  
Al-Dirbashi OY, 2014, JIMD REP, V16, P65, DOI 10.1007/8904_2014_321
[2]  
American College of Medical Genetics and Genomics, 2001, ACT SHEETS CONF ALG
[3]   Precision newborn screening for lysosomal disorders [J].
Baerg, Melissa M. Minter ;
Stoway, Stephanie D. ;
Hart, Jeremy ;
Mott, Lea ;
Peck, Dawn S. ;
Nett, Stephanie L. ;
Eckerman, Jason S. ;
Lacey, Jean M. ;
Turgeon, Coleman T. ;
Gavrilov, Dimitar ;
Oglesbee, Devin ;
Raymond, Kimiyo ;
Tortorelli, Silvia ;
Matern, Dietrich ;
Morkrid, Lars ;
Rinaldo, Piero .
GENETICS IN MEDICINE, 2018, 20 (08) :847-854
[4]   Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns [J].
Chace, DH ;
Kalas, TA ;
Naylor, EW .
CLINICAL CHEMISTRY, 2003, 49 (11) :1797-1817
[5]   Improving newborn screening laboratory test ordering and result reporting using health information exchange [J].
Downs, Stephen M. ;
van Dyck, Peter C. ;
Rinaldo, Piero ;
McDonald, Clement ;
Howell, R. Rodrey ;
Zuckerman, Alan ;
Downing, Gregory .
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2010, 17 (01) :13-18
[6]   Rapid determination of C4-acylcarnitine and C5-acylcarnitine isomers in plasma and dried blood spots by UPLC-MS/MS as a second tier test following flow-injection MS/MS acylcarnitine profile analysis [J].
Forni, Sabrina ;
Fu, Xiaowei ;
Palmer, Susan E. ;
Sweetman, Lawrence .
MOLECULAR GENETICS AND METABOLISM, 2010, 101 (01) :25-32
[7]  
Fu XW, 2013, JIMD REP, V10, P69, DOI 10.1007/8904_2012_205
[8]  
Gabler E., 2016, MILWAUKEE J SENTIN
[9]  
Gallagher R.C., INT J NEONATAL SCREE
[10]   Newborn Screening for Lysosomal Storage Diseases: Methodologies, Screen Positive Rates, Normalization of Datasets, Second-Tier Tests, and Post-Analysis Tools [J].
Gelb, Michael H. .
INTERNATIONAL JOURNAL OF NEONATAL SCREENING, 2018, 4 (03)